Vall d’Hebron Institute of Research (VHIR) has signed an agreement with "http://www.fundacionprobitas.org/" Probitas Foundation and the "http://hospitalnsdelapaz.blogspot.com.es/" Nossa Senhora da Paz Hospital in Cubal, in the east-central region of Angola, to improve the prognosis and the quality of life of patients with drug-resistant tuberculosis. The agreement will promote the first national study on the real resistance rate to anti-tuberculosis drugs in Angola.In the coming three years, 498,000 euros will be dedicated for the renovation of the laboratory, the training of the local staff in the hospital, the assessment of the therapeutic plan and the creation of an epidemiology surveillance system in the African hospital, which offers medical coverage to over 250,000 inhabitants from the rural area of Cubal. The Angolan Health Department will pay €310,000, Probitas Foundation, €98,000, the Tropical Medicine and International Health Unit at Vall d’Hebron University Hospital, €69.900, and Nossa Senhora da Paz Hospital, €20,700. The project will strengthen the use of the biological diagnostics laboratory through the implementation of a genotypic technique that will enable the quickly and correct diagnosis of tuberculosis. Local staff will be also trained in order to realize the molecular diagnostic techniques with sputum samples. Once the data was obtained, researchers from the Microbiology group, led by Dr. Tomàs Pumarola at VHIR, will receive over 500 samples from the hospital in Cubal, with the aim to carry out a study of the anti-TB drug susceptibility. Researchers from the Microbiology Service will work closer with the Infectious Diseases team at Vall d’Hebron, led by Dr. Albert Pahissa. The epidemiologic knowledge of drug-resistant tuberculosis will allow the development of appropriate therapeutic guidelines to reduce the high morbidity and mortality rate in the region, and will be convenient to reevaluate, in case of necessary, the guidelines of the Angolan National Health System.